Sagimet Biosciences Inc. Series A Common Stock (SGMT) financials · $403.2M cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Sagimet Biosciences Inc. Series A Common Stock (SGMT) $403.2M cap.
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Income | -$56.9M | -$54.5M |
| Net Income | -$51.0M | -$45.6M |
| EPS (Diluted) | -$1.58 | -$1.45 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $116.5M | $160.3M |
| Current Assets | $116.4M | $152.8M |
| Cash & Equivalents | $35.0M | $75.8M |
| Total Liabilities | $5.10M | $4.45M |
| Current Liabilities | $5.10M | $4.45M |
| Shareholders' Equity | $111.4M | $155.8M |
| Retained Earnings | -$346.3M | -$295.3M |
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$45.6M | -$42.4M |
| Investing Cash Flow | $4.56M | -$61.7M |
| Financing Cash Flow | $275.0K | $104.8M |
FAQ
What is SGMT P/E and revenue?
Sagimet Biosciences Inc. Series A Common Stock (SGMT) $403.2M cap.
What is SGMT revenue?
SGMT income-statement cache has no revenue figure yet.
Is SGMT profitable?
Sagimet Biosciences Inc. Series A Common Stock last cached net income is -$51.0M (FY2025).
What are SGMT total assets?
Sagimet Biosciences Inc. Series A Common Stock last cached total assets are $116.5M (FY2025).
What is SGMT free cash flow?
No cached cash-flow row for SGMT yet.
Not investment advice. Cached statements, not a live tape.